MSB.AX - Mesoblast Limited

ASX - ASX Delayed Price. Currency in AUD

Mesoblast Limited

55 Collins Street
Level 38
Melbourne, VIC 3000
61 3 9639 6036

Full Time Employees81

Key Executives

NameTitlePayExercisedYear Born
Dr. Silviu ItescuFounder, CEO, MD, Chairman of Scientific Advisory Board & Exec. Director2.03MN/A1957
Dr. Donna L. SkerrettChief Medical OfficerN/AN/A1957
Mr. Roger D. Brown BAHead of Spinal Orthopedic DisordersN/AN/AN/A
Mr. Michael Schuster MS, BSc, MBAHead of Pharma PartneringN/AN/A1977
Dr. Kenneth M. Borow M.D.Exec.N/AN/A1948
Amounts are as of December 31, 2018 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in AUD.


Mesoblast Limited, a biopharmaceutical company, develops and commercializes allogeneic cellular medicines. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage adult stem cells. The company's products under the Phase III clinical trials include MSC-100-IV for steroid refractory acute graft versus host disease; MPC-150-IM for advanced heart failure; and MPC-06-ID for chronic low back pain due to degenerative disc disease. It is also developing MPC-300-IV that is in Phase II clinical trials for the treatment of biologic refractory rheumatoid arthritis, diabetic kidney diseases, and type 2 diabetic nephropathy. It operates in the United States, Australia, Singapore, the United Kingdom, and Switzerland. Mesoblast Limited has strategic partnerships with Tasly Pharmaceutical Group to offer MPC-150-IM for heart failure and MPC-25-IC for heart attacks in China; and JCR Pharmaceuticals Co. Ltd. for the treatment of wound healing in epidermolysis bullosa. The company was founded in 2004 and is headquartered in Melbourne, Australia.

Corporate Governance

Mesoblast Limited’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.